Rich Insights into the Hot Flashes Market, Epidemiology Segmentation, Emerging Drugs and Key Companies in the Industry

Hot Flashes Market

DelveInsight’s Hot Flashes market report provides an in-depth understanding of the Hot Flashes, historical and forecasted epidemiology, as well as Hot Flashes market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan). The report also discusses current Hot Flashes treatment practices/algorithms, Hot Flashes market drivers, Hot Flashes market barriers, and unmet medical needs. 

Some of the Crucial Highlights from the Hot Flashes Market Report

• As per DelveInsight Hot Flashes epidemiology insights, the United States has the highest prevalent population with over 18 million cases in 2018. The prevalence of mild Hot Flashes was maximum as compared to moderate and severe.

• Among the EU5 countries, Germany had the highest Hot Flashes prevalent population while Spain had the lowest in 2018.

• Various pharmaceutical companies such as Mithra Pharmaceuticals, Astellas Pharma, Bayer, Fervent Pharmaceuticals, Sojournix, and others are developing therapies for Hot Flashes treatment that are projected to enter the US market by 2030.

• Donesta (Mithra Pharmaceuticals) is an E4-based hormone therapy (HT) candidate for the relief of Vasomotor Menopausal Symptoms (VMS). Currently, it is in Phase III clinical trials for Hot Flashes treatment.

• Fezolinetant (Astellas Pharma) is a proprietary, oral, small-molecule discovered for the treatment of women’s health disorders, and it is expected to have the greatest impact on the nonhormonal therapeutic market of Hot Flashes associated with menopause.

• The treatment of Menopausal Hot Flashes with NK3 antagonism is a new clinically and genetically validated approach.

• Some of the other promising therapies which are in the pipeline for Hot Flashes treatment include FP-101 (Fervent Pharmaceuticals), NT-814 (Bayer), and SJX-653 (Sojournix).

Request for the sample to get an overview about the disease @ Hot Flashes Market

The Hot Flashes market report covers current treatment practices, Hot Flashes emerging drugs, individual therapy Hot Flashes market share, current and forecasted Hot Flashes market Size from 2018 to 2030, segmented by seven major markets.

Hot Flashes: Overview

Hot Flashes, also known as Vasomotor Symptoms (VMS) are the most prevalent menopausal symptoms. They are characterized by a sudden increase in blood flow, usually to the face, neck, and chest, which causes severe heat and profuse sweating. Night sweats are a type of symptom that occurs at night and can cause considerable sleep problems.

Hot Flashes Epidemiology Segmentation

The Hot Flashes report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Hot Flashes Total Prevalent Pool

• Hot Flashes Severity-Specific Prevalent Pool

Hot Flashes Treatment Landscape

The current Hot Flashes therapeutic landscape is divided into two categories- Hormonal Therapies and Non Hormonal Therapies. Some of the FDA approved Hormonal Therapies for Hot Flashes treatment include Premarin (Pfizer), Menest (Pfizer), Alora (Allergan), Climara Pro (Bayer Healthcare), MINIVELLE (Noven Therapeutics), Evamist (Perrigo Pharma), Elestrin (DPT Laboratories), Bijuva (TherapeuticsMD), and others.

On the other hand, nonhormonal therapies such as antidepressants, gabapentin, and clonidine, are used to treat vasomotor symptoms associated with menopause. Brisdelle is the first and only non-hormonal antidepressant to be approved for Vasomotor Symptoms treatment.

Hot Flashes Market

• The Hot Flashes market size was found to be USD 1,755.8 million in 7MM in 2018.

• The United States accounted for 61% USD of the overall Hot Flashes market share while among the EU5 countries, Germany had the highest Hot Flashes market size.

• Owing to the launch of upcoming therapies such as Donesta (Mithra Pharmaceuticals), Fezolinetant (Astellas Pharma), NT-814 (Bayer), FP-101 (Fervent Pharmaceuticals), SJX-653 (Sojournix), and others, the Hot Flashes market size is anticipated to boost during the forecast period (2021-2030).

To find out the menopausal hot flashes drugs market, visit Hot Flashes Drugs

Hot Flashes Pipeline Therapies and Key Companies

• Donesta: Mithra Pharmaceuticals

• Fezolinetant: Astellas Pharma

• NT-814: Bayer

• FP-101: Fervent Pharmaceuticals

• SJX-653: Sojournix

Hot Flashes Market Drivers

• Increasing awareness

• Rising emerging therapies

Hot Flashes Market Barriers

• Generic nature of the market

• Limited understanding of Pathophysiology

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Hot Flashes Key Companies: Mithra Pharmaceuticals, Astellas Pharma, Bayer, Fervent Pharmaceuticals, Sojournix, among others. 

Hot Flashes Key Pipeline Therapies: Donesta, Fezolinetant, NT-814, FP-101, SJX-653,and others.

Hot Flashes Segmentation: By Geography, Hot Flashes drugs

Analysis: Comparative and conjoint analysis of  Hot Flashes emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Polycystic Ovarian Syndrome Market 

Get comprehensive historical and forecast analysis of Polycystic Ovarian Syndrome Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Zydus Discovery DMCC, Spruce Biosciences, Kindex Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/